AUTL – autolus therapeutics plc - american depositary shares (US:NASDAQ)
Stock Stats
News
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress [Yahoo! Finance]
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
Form 10-Q Autolus Therapeutics For: Mar 31
Form 8-K Autolus Therapeutics For: May 17
Form NT 10-Q Autolus Therapeutics For: May 13
Form 8-K Autolus Therapeutics For: May 13
Form 8-K Autolus Therapeutics For: Mar 26
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.